Groundbreaking instrument-free assay nears completion, showing promise for faster, more accurate patient care.
NEW YORK, NY, April 10, 2025 / Biotech Newswire / -- Chemeleon, a disruptive innovator in diagnostic technology, today announced a collaboration with Mayo Clinic to complete development and clinical validation of their ultra-rapid, instrument-free assay poised to redefine point-of-care (POC) testing in emergency settings. This collaboration will focus on clinical optimization of Chemeleon’s flagship high-sensitivity cardiac troponin (hs-cTn) assay and explore the application of their platform technology to other acute care conditions beyond cardiac care. Coinciding with this milestone, the company has opened a $10M Series A funding round to help bring this transformative technology to market.
The ultra-rapid, POC assay leverages Chemeleon’s patented Binding-Induced Nanostructured Dynamic Surface (BINDS™) technology to deliver results in seconds rather than hours, dramatically accelerating clinical-decision making and transforming patient outcomes. Collaborating with Mayo Clinic enables enhanced clinical validation, diagnostic protocol optimization, and a clear path to adoption. “With Mayo Clinic’s deep clinical expertise, we’re accelerating a future where faster diagnosis can mean faster treatment for life-threatening conditions in and out of the emergency department,” said Brendan Walker, CEO of Chemeleon.
The Series A will fund clinical trials, FDA clearance, and initial market entry into a $15 billion acute care diagnostics market. Investors interested in exploring this opportunity can join a briefing on Wednesday, April 16th at 2:00 PM ET (REGISTER HERE) or Wednesday, April 23rd at 2:00 PM ET (REGISTER HERE) to learn more.
About Chemeleon
Chemeleon develops ultra-rapid, instrument-free, POC assays that deliver lab-precision results at the point of need. By enabling faster clinical decision-making, Chemeleon’s patented technology is designed to improve patient outcomes in acute and emergency care.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Contact
Chemeleon
Brendan Walker
This email address is being protected from spambots. You need JavaScript enabled to view it..
Keywords: Investments; Capital Financing; Point-of-Care Systems; Point-of-Care Testing; Technology; Decision Making; Troponin I; Chemeleon; Mayo Clinic; ultra-rapid assay; Series A; diagnostic technology; clinical validation; POC testing; emergency settings; high-sensitivity cardiac troponin (hs-cTn) assay; acute care conditions; Binding-Induced Nanostructured Dynamic Surface (BINDSTM); clinical decision-making; patient outcomes; clinical trials; FDA clearance; acute care diagnostics market; emergency care
Source: Biotech Newswire